Bruker & Murdoch University strategic collaboration announced for phenomics

September 20, 2019 -- On Friday, September 20, 2019, Murdoch University (Perth, Australia) and Bruker (Billerica, Massachusetts) announced a strategic collaboration to transform the prevention and diagnosis of disease and personalized health. The efforts will be focused within the Australian National Phenome Centre (ANPC), an international center of expertise for metabolic phenotyping.

Image caption: Avance IVDr systems for NMR- based phenomics at Murdoch University

The ANPC will house various Bruker nuclear magnetic resonance (NMR) and mass spectrometry (MS) phenomics equipment that will enable searchers to examine the complex interactions of genes, the environment, and lifestyle on human metabolic health. ANPC will work closely with major hospitals, universities and medical research institutes in the greater context of the Western Australian Health Translational Network (WAHTN).

Murdoch University will house multiple state-of-the-art Bruker phenomics solutions, including seven AVANCE® IVDr 600 MHz NMRs, one NMR FoodScreener™, an ESI & MALDI MRMS (Magnetic Resonance Mass Spectrometry) system for high-throughput flow-injection analysis (FIA) MRMS workflows, twelve impact-II QTOF and two timsTOF™ systems.

"We're thrilled that Bruker, a world-leading manufacturer of research equipment, will contribute its technological and research expertise to help us improve health outcomes around the world," added Professor Nicholson. "Phenomics is a key next step in expanding the boundaries of our knowledge of human health and the causes and prevention of disease. The strategic alliance between Murdoch University and Bruker enhances the valuable work of the ANPC by bringing state-of-the-art instruments and experienced researchers in this space to Western Australia. It reflects the growing focus and investment in precision medicine in the Asia Pacific region and will help us to transform how long and how well people live, not just in Australia, but around the world."

"Phenomics research continues to evolve and offers fascinating insights into disease processes. With our expertise in both mass spectrometry and nuclear magnetic resonance, we are able to harness the unique and differentiated potential of each technique and partner with researchers to combine the best tools required for their metabolomics research." said Dr. Manfred Spraul, CTO of Bruker's Applied, Industrial & Clinical magnetic resonance division.

Copyright © 2019

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter